Prism BioLab

Fujisawa, Japan

Prism is a biotechnology company that develops therapeutic drugs that cure intractable diseases using unique peptide mimic technology.

$10.2M raised

Jan 2024

Series C

Top Investors

Eli LillyDaiwa Corporate InvestmentJAFCOWM PartnersEisai

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Prism BioLab raised?

Prism BioLab has raised $10.2M in total funding. The most recent round was Series C. The last funding was announced in January 2024.

Who are Prism BioLab's investors?

Prism BioLab's investors include Eli Lilly, Daiwa Corporate Investment, JAFCO, WM Partners, Eisai.

Where is Prism BioLab headquartered?

Prism BioLab is headquartered in Fujisawa, Japan.

What does Prism BioLab do?

Prism is a biotechnology company that develops therapeutic drugs that cure intractable diseases using unique peptide mimic technology.

What stage is Prism BioLab at?

Prism BioLab is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 24, 2024.

MLA

"Prism BioLab — Funding & Investors." VCBacked, January 24, 2024, https://www.vcbacked.co/company/prism-biolab. Accessed June 15, 2026.

APA

VCBacked. (2024). Prism BioLab — Funding & Investors. Retrieved June 15, 2026, from https://www.vcbacked.co/company/prism-biolab

Wikipedia (cite web)

{{cite web |title=Prism BioLab — Funding & Investors |url=https://www.vcbacked.co/company/prism-biolab |website=VCBacked |access-date=June 15, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 24, 2024.